Ace Therapeutics launches its full suite of ocular toxicology services to support global pharmaceutical and biotech clients in advancing safe and effective ophthalmic therapies.
NEW YORK, NY, April 23, 2026 /24-7PressRelease/ — Ace Therapeutics, a specialized preclinical contract research organization (CRO) focused on ophthalmic drug development, launches its full suite of ocular toxicology services to support global pharmaceutical and biotech clients in advancing safe and effective ophthalmic therapies. Its robust preclinical ocular toxicology studies are designed to meet stringent regulatory requirements and streamline the investigational new drug (IND) application pathway.
Ocular toxicology evaluations are a critical component of ophthalmic product development, as unaddressed ocular toxicity can lead to eye discomfort, tissue damage, or irreversible vision impairment. Ace Therapeutics designs studies to identify potential adverse structural or functional changes to ocular tissues following local or systemic administration, supporting data-driven safety decisions throughout drug discovery.
Ace Therapeutics’ ocular toxicology services cover a complete spectrum of assessments, including acute, subacute, and chronic local toxicity evaluation, maximum tolerated dose (MTD) determination, ocular tolerance testing, lacrimation assessment, corneal anesthesia analysis, and pupil diameter measurement. These evaluations are supported by clinical ophthalmic examinations, visual system imaging and electrophysiology, histopathological analysis, and systemic safety profiling to deliver holistic safety data.
These preclinical ocular toxicology studies can be customized to project-specific needs and aligned with the latest international regulatory guidelines. Studies are conducted across multiple preclinical species, including mice, rats, guinea pigs, rabbits, canines, pigs, minipigs, and non-human primates, with flexible administration routes such as intravitreal, intracameral, subconjunctival, subretinal, topical, and systemic delivery. Local tolerance assessments can be performed as standalone modules or integrated into broader toxicology programs to optimize efficiency and reduce development risks prior to IND submission.
“We combine deep ophthalmic toxicology expertise with advanced technical platforms to deliver reliable, regulatory-ready safety data. Our tailored ocular toxicology services and rigorous preclinical ocular toxicology studies help sponsors mitigate risks, accelerate timelines, and strengthen their IND packages with confidence,” said the business development manager at Ace Therapeutics.
Key advantages of Ace Therapeutics’ offering include personalized study design, a team of seasoned ophthalmic toxicology specialists, end-to-end technical support for data interpretation, and strict adherence to updated regulatory standards. By serving as an extension of clients’ research teams, Ace Therapeutics enables efficient progression from early-stage screening to late-stage preclinical safety validation.
With these expanded capabilities, Ace Therapeutics reinforces its position as a trusted global partner for ophthalmic drug safety assessment, supporting the development of innovative treatments for a wide range of ocular diseases and conditions.
Ace Therapeutics is a leading preclinical contract research organization (CRO) based in New York, specializing in the development of customized disease models and preclinical research services across multiple therapeutic areas. Ace Therapeutics provides one-stop preclinical solutions including efficacy testing, pharmacokinetic analysis, toxicology studies and biomarker development for pharmaceutical companies, academic institutions and research organizations worldwide.
—
For the original version of this press release, please visit 24-7PressRelease.com here
Legal Disclaimer: This article was provided by an independent third-party content provider. Kyrion Media makes no warranties or representations in connection with it. All information is provided “as is” without warranty of any kind. This content may not have been reviewed by our editorial staff and is published automatically. The views expressed in this article are those of the author and do not necessarily reflect the views of Kyrion Media. All trademarks are the property of their respective owners. If you are affiliated with this article and would like it removed, please contact retract@kyrionmedia.com.
